9/25/2013

The National Cancer Institute has awarded MabVax Therapeutics a $1.75 million contract through its Small Business Innovation Research program. MabVax will use the funding to develop a novel PET imaging agent for diagnosing, staging and evaluating treatment for patients with pancreatic cancer.

Related Summaries